Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
1. Hims & Hers will offer generic semaglutide in Canada post-Novo Nordisk's patent expiry. 2. The Canadian semaglutide market is projected to grow to $4.03 billion by 2035. 3. Hims will prioritize affordable and personalized weight loss care solutions in Canada. 4. The company's recent acquisition of Zava expands its telehealth services in Europe. 5. Novo Nordisk's collaboration with Hims was terminated due to concerns over generic promotions.